Rice Hall James & Associates LLC raised its stake in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 25.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 621,665 shares of the company's stock after purchasing an additional 124,438 shares during the quarter. Rice Hall James & Associates LLC owned approximately 1.72% of scPharmaceuticals worth $2,835,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Perkins Capital Management Inc. purchased a new position in shares of scPharmaceuticals during the first quarter valued at about $53,000. Virtu Financial LLC purchased a new position in shares of scPharmaceuticals during the 1st quarter worth approximately $90,000. Balanced Rock Investment Advisors LLC raised its position in shares of scPharmaceuticals by 10.3% in the 2nd quarter. Balanced Rock Investment Advisors LLC now owns 63,130 shares of the company's stock worth $275,000 after acquiring an additional 5,882 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of scPharmaceuticals by 266.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 72,692 shares of the company's stock valued at $316,000 after purchasing an additional 52,870 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of scPharmaceuticals by 15.1% during the second quarter. Bank of New York Mellon Corp now owns 86,101 shares of the company's stock valued at $375,000 after purchasing an additional 11,269 shares in the last quarter. 89.52% of the stock is currently owned by institutional investors.
Shares of NASDAQ SCPH opened at $4.07 on Friday. The stock has a market cap of $203.62 million, a P/E ratio of -2.61 and a beta of 0.13. The company has a debt-to-equity ratio of 4.32, a current ratio of 4.84 and a quick ratio of 3.66. scPharmaceuticals Inc. has a 1 year low of $3.24 and a 1 year high of $6.71. The firm has a 50-day moving average of $4.70 and a 200 day moving average of $4.53.
scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.44) EPS for the quarter, hitting analysts' consensus estimates of ($0.44). The firm had revenue of $8.05 million for the quarter, compared to analysts' expectations of $8.04 million. scPharmaceuticals had a negative return on equity of 201.84% and a negative net margin of 252.18%. As a group, sell-side analysts expect that scPharmaceuticals Inc. will post -1.34 EPS for the current fiscal year.
Separately, HC Wainwright reissued a "buy" rating and set a $18.00 price objective on shares of scPharmaceuticals in a research report on Monday, August 19th.
Get Our Latest Analysis on scPharmaceuticals
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider scPharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and scPharmaceuticals wasn't on the list.
While scPharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.